Astec LifeSciences Limited has informed the Exchange about Credit Rating
ASTEC · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
ICRA Limited has reaffirmed its credit ratings on Astec LifeSciences' debt instruments as of March 24, 2026. The long-term fund-based cash credit facility of Rs.283 crore and term loan facility of Rs.100 crore retain the ICRA AA- rating, but carry a 'Negative' outlook. The short-term non-fund based facilities of Rs.335 crore, commercial paper programme of Rs.300 crore, and non-convertible debenture programme of Rs.50 crore were all reaffirmed at ICRA A1+ (or AA- with Negative outlook for the NCD). Total rated debt covered comes to Rs.768 crore across all instruments. ICRA retained the same ratings rather than upgrading or downgrading them, but flagged the Negative outlook on long-term ratings which signals possible future downgrade if conditions worsen.
For shareholders, the rating is unchanged so no immediate positive or negative surprise, but the 'Negative' outlook on long-term borrowings indicates ICRA sees some risk factors that could lead to a downgrade if they don't improve. Investors should watch for any deterioration in business or financial metrics over the coming year.